专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010065541A2 BIOMARKERS USEFUL IN LIVER FIBROSIS DIAGNOSIS 审中-公开
标题翻译：生物标志物在肝纤维化诊断中的应用
公开(公告)号：WO2010065541A2
公开(公告)日：2010-06-10
申请号：PCT/US2009/066258
申请日：2009-12-01
申请人： TSENG, Tzu-Ling , LI, Hung-Yi , LI, Yen-Peng , LEE, Angelina Huai-Lo , LIU, Yi-Chen , CHENG, Ping-Fu , LIN, Wei-Ya , YEH, Hong-Zen
发明人： TSENG, Tzu-Ling , LI, Hung-Yi , LI, Yen-Peng , LEE, Angelina Huai-Lo , LIU, Yi-Chen , CHENG, Ping-Fu , LIN, Wei-Ya , YEH, Hong-Zen
IPC分类号： G01N33/68 , G01N33/53 , C12Q1/68
CPC分类号： G01N33/6893 , G01N33/487 , G01N33/49 , G01N33/50 , G01N33/5067 , G01N33/53 , G01N33/576 , G01N2333/70539 , G01N2333/96494 , G01N2333/9723 , G01N2800/085
摘要： Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and β -2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.
摘要翻译：鉴定尿激酶型纤溶酶原，基质金属蛋白酶9和β-2-微球蛋白作为与肝纤维化相关的新型生物标志物及其在诊断肝纤维化中的用途。

2. 发明申请

WO2003073910A2 ASSAYS FOR CANCER PATIENT MONITORING BASED ON LEVELS OF ANALYTE COMPONENTS OF THE PLASMINOGEN ACTIVATOR SYSTEM IN BODY FLUID SAMPLES 审中-公开
标题翻译：基于体液激素系统分析物组分在体液样本中的癌症患者监测分析
公开(公告)号：WO2003073910A2
公开(公告)日：2003-09-12
申请号：PCT/US2003/005957
申请日：2003-02-27
申请人： BAYER CORPORATION
发明人： CARNEY, Walter, P. , HAMER, Peter, J.
IPC分类号： A61B
CPC分类号： G01N33/57484 , G01N33/86 , G01N2333/8132 , G01N2333/9723 , G01N2800/52 , Y10T436/25
摘要： The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.
摘要翻译：本发明描述了临床和医学上重要的检查，随时间筛选和监测正在接受他或她的疾病的治疗或治疗的癌症患者的结果的重要方法。更具体地说，本发明提供了通过测量纤溶酶原激活剂（uPA）系统的一种或多种分析物（即uPA，PAI-1）的水平来监测癌症患者的疾病进展或癌症治疗的有效性的方法， 1和uPA：PAI-1的复合物在取自癌症患者的样品中，优选在治疗之前，在治疗开始时以及在治疗期间的不同时间间隔进行。作为实施该方法的结果，与正常对照个体中的一种或多种相应PA系统分析物的水平相比，癌症患者中的一种或多种PA系统分析物的水平的升高或升高用作癌症进展或进展和/或对患者缺乏治疗效果。

3. 发明申请

WO02016929A2 UROKINASE PEPTIDE STRUCTURE MIMETICS 审中-公开
标题翻译： UROKINASE肽结构的MIME类型
公开(公告)号：WO02016929A2
公开(公告)日：2002-02-28
申请号：PCT/EP2001/009668
申请日：2001-08-21
IPC分类号： C12N9/72 , G01N33/573 , G01N33/00
CPC分类号： G01N33/573 , G01N2333/9723 , G01N2500/00
摘要： The NMR structure of the peptidic urokinase type plasminogen activator antagonist cyclo[21,29][D-Cys21Cys29]-uPA21-30 has been solved to identify design strategies for peptidomimetics that interfere with the binding of urokinase type plasminogen activator with its receptor.
摘要翻译：已经解决了肽尿激酶型纤溶酶原激活剂拮抗剂环[21,29] [D-Cys21Cys29] -uPA21-30的NMR结构，以鉴定干扰尿激酶型纤溶酶原激活物与其受体结合的肽模拟物的设计策略。

4. 发明申请

WO9945389A3 LIGAND SCREENING AND DESIGN BY X-RAY CRYSTALLOGRAPHY 审中-公开
标题翻译：通过X射线晶体学的配镜筛选和设计
公开(公告)号：WO9945389A3
公开(公告)日：2000-02-10
申请号：PCT/US9904518
申请日：1999-03-01
申请人： ABBOTT LAB
发明人： NIENABER VICKI L , GREER JONATHAN , ABAD-ZAPATERO CELERINO , NORBECK DANIEL W
IPC分类号： G01N33/50 , G01N23/20 , G01N33/15 , G01N33/53 , G01N33/68 , C30B7/00
CPC分类号： G01N33/6845 , C07K2299/00 , C30B7/00 , G01N23/20 , G01N33/68 , G01N33/6803 , G01N33/6842 , G01N2333/9723 , G01N2500/00
摘要： X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed. The target is exposed to the test samples by either co-crystallizing a biomolecule in the presence of one or more test samples or soaking the biomolecule crystal in a solution of one or more test samples. In another embodiment, structural information from ligand/receptor complexes are used to design ligands that bind tighter, that bind more specifically, that have better biological activity or that have better safety profile. A further embodiment of the invention comprises identifying or designing biologically-active moieties by the instant process. In a further embodiment, a biomolecule crystal having an easily accessible active site is formed by co-crystallizing the biomolecule with a degradable ligand and degrading the ligand.
摘要翻译：可以使用X射线晶体学来筛选不具有目标生物分子配体的化合物，以获得其结合目标生物分子的能力。该方法包括获得目标生物分子的晶体; 将目标生物分子晶体暴露于一个或多个测试样品; 并获得X射线晶体衍射图，以确定是否形成配体/受体复合物。通过在一个或多个测试样品的存在下共生结晶生物分子或将生物分子晶体浸泡在一个或多个测试样品的溶液中，将靶标暴露于测试样品。在另一个实施方案中，来自配体/受体复合物的结构信息用于设计更具结合性，更具体地具有更好生物活性或具有更好安全性的配体。本发明的另一个实施方案包括通过本方法识别或设计生物活性部分。在另一个实施方案中，具有易于接近的活性位点的生物分子晶体通过使生物分子与可降解配体共结晶并降解配体而形成。

5. 发明申请

WO1999045389A2 LIGAND SCREENING AND DESIGN BY X-RAY CRYSTALLOGRAPHY 审中-公开
标题翻译：通过X射线晶体学的配镜筛选和设计
公开(公告)号：WO1999045389A2
公开(公告)日：1999-09-10
申请号：PCT/US1999004518
申请日：1999-03-01
申请人： ABBOTT LABORATORIES
发明人： ABBOTT LABORATORIES , NIENABER, Vicki, L. , GREER, Jonathan , ABAD-ZAPATERO, Celerino , NORBECK, Daniel, W.
IPC分类号： G01N33/50
CPC分类号： G01N33/6845 , C07K2299/00 , C30B7/00 , G01N23/20 , G01N33/68 , G01N33/6803 , G01N33/6842 , G01N2333/9723 , G01N2500/00
摘要： X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crystal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed. The target is exposed to the test samples by either co-crystallizing a biomolecule in the presence of one or more test samples or soaking the biomolecule crystal in a solution of one or more test samples. In another embodiment, structural information from ligand/receptor complexes are used to design ligands that bind tighter, that bind more specifically, that have better biological activity or that have better safety profile. A further embodiment of the invention comprises identifying or designing biologically-active moieties by the instant process. In a further embodiment, a biomolecule crystal having an easily accessible active site is formed by co-crystallizing the biomolecule with a degradable ligand and degrading the ligand.
摘要翻译：可以使用X射线晶体学来筛选目标生物分子的未知配体的化合物，以获得其结合目标生物分子的能力。该方法包括获得目标生物分子的晶体; 将目标生物分子晶体暴露于一个或多个测试样品; 并获得X射线晶体衍射图，以确定是否形成配体/受体复合物。通过在一个或多个测试样品的存在下共生结晶生物分子或将生物分子晶体浸泡在一个或多个测试样品的溶液中，将靶标暴露于测试样品。在另一个实施方案中，来自配体/受体复合物的结构信息用于设计更紧密结合的配体，其更具体地结合，具有更好的生物活性或具有更好的安全性。本发明的另一个实施方案包括通过本方法识别或设计生物活性部分。在另一个实施方案中，通过使生物分子与可降解配体共结晶并使配体降解而形成具有易于接近的活性位点的生物分子晶体。

6. 发明申请

WO2015006713A1 DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK 审中-公开
标题翻译：诊断心血管危险因素的诊断
公开(公告)号：WO2015006713A1
公开(公告)日：2015-01-15
申请号：PCT/US2014046386
申请日：2014-07-11
申请人： UNIV EMORY
发明人： QUYYUMI ARSHED A
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4737 , G01N2333/70596 , G01N2333/75 , G01N2333/9723 , G01N2800/32 , G01N2800/324 , G01N2800/60 , G01N2800/7004 , G01N2800/7095
摘要： This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), urokinase or urokinase receptor (uPA/uPAR), and/or anti-CMV antibody.
摘要翻译：本发明涉及心血管疾病的领域，具体涉及使用标记物的组合来预测个体发展冠状动脉疾病（CAD）和相关疾病如心绞痛和外周血管疾病的风险的诊断测试方法，以及更多特别是确定个体的心肌梗塞，死亡和中风的风险。示例性生物标志物包括C反应蛋白（CRP），纤维蛋白降解产物（FDP），热休克蛋白70（HSP70），尿激酶或尿激酶受体（uPA / uPAR）和/或抗CMV抗体。

7. 发明申请

WO2009091581A3 DIAGNOSTIC BIOMARKERS FOR VASCULAR ANEURYSM 审中-公开
标题翻译：诊断生物标志物用于血管病变
公开(公告)号：WO2009091581A3
公开(公告)日：2009-10-22
申请号：PCT/US2009000276
申请日：2009-01-16
申请人： VATRIX MEDICAL INC , OGLE MATTHEW F , ISENBURG JASON C
发明人： OGLE MATTHEW F , ISENBURG JASON C
IPC分类号： G01N33/68 , G01N33/50 , G01N33/573
CPC分类号： G01N33/6887 , G01N2333/78 , G01N2333/96494 , G01N2333/9723 , G01N2333/9726 , G01N2800/329 , Y10T436/173845
摘要： Biomarkers for diagnosis and monitoring of vascular aneurysms are described in the context of the use of assays to measure a plurality of these biomarkers. Tissue degeneration, particularly elastin and/or collagen degradation, can be monitored within patient blood (serum) and/or urine to diagnose the presence, the progression, or the likelihood of rupture of aneurismal disease. Additionally, enzymes responsible for this degradation and other biomarkers responsible for the activation or inhibition of these enzymes can be monitored additionally or alternatively. Prompt diagnosis can provide the opportunity for intervention and potentially increase the health of patients by tempering the development of debilitating and life-threatening vascular aneurysms.
摘要翻译：用于诊断和监测血管动脉瘤的生物标志物在使用测定来测量多个这些生物标志物的背景下进行了描述。可以在患者血液（血清）和/或尿液内监测组织变性，特别是弹性蛋白和/或胶原降解，以诊断动脉瘤疾病破裂的存在，进展或可能性。此外，负责这种降解的酶和负责这些酶的活化或抑制的其他生物标志物可以被附加地或替代地监测。快速诊断可以提供干预的机会，并通过回火衰老和威胁生命的血管动脉瘤的发展来增加患者的健康。

8. 发明申请

WO99043311A3 CONJUGATED SURAMIN OR DERIVATIVES THEREOF WITH PEG, POLYASPARTATE OR POLYGLUTAMATE FOR CANCER TREATMENT 审中-公开
标题翻译：与PEG，聚氨酯或聚氨基葡萄糖相结合的磺胺或其衍生物用于癌症治疗
公开(公告)号：WO99043311A3
公开(公告)日：1999-10-14
申请号：PCT/US1999/004336
申请日：1999-02-26
IPC分类号： A61K47/48 , C09B69/10 , C12Q1/37 , A61K31/185
CPC分类号： C12Q1/37 , A61K47/60 , A61K47/645 , C09B69/106 , G01N2333/9723
摘要： The present invention provides an assay that identifies compounds which inhibit cleavage of HGF/SF by serum proteases such as uPA, and methods in which such compounds are provided to reaction solutions, to cultured cells in vitro, or to a mammal in vivo, to inhibit cleavage of HGF/SF and to inhibit chemical and biological effects resulting from the activation of c-Met receptor by HGF/SF. The invention also provides methods for modifying suramin and suramin-related polysulfonated compounds that inhibit HGF/SF cleavage, by attaching PEG or polyanions such as polyglutamate or polyaspartate to the compounds to reduce cellular uptake of the compounds, thereby reducing their cytotoxicity. Also provided are a pharmaceutical composition containing at least one polysulfonated HGF/SF cleavage-inhibiting compound other than suramin, and a pharmaceutical composition containing at least one HGF/SF cleavage-inhibiting form of suramin or a suramin-related polysulfonated compound that is modified by conjugation to a chemical moiety that reduces uptake of the compound into cells. The present invention further includes methods wherein such pharmaceutical compositions are administered to a mammal with a tumor that is stimulated to grow by HGF/SF, to inhibit the growth or metastasis of the tumor in the mammal.
摘要翻译：本发明提供了鉴定抑制血清蛋白酶如uPA抑制HGF / SF切割的化合物的方法，以及将这些化合物提供给反应溶液，体外培养的细胞或体内哺乳动物的方法抑制 HGF / SF的切割并抑制由HGF / SF激活c-Met受体引起的化学和生物学作用。本发明还提供了通过将PEG或聚阴离子例如聚谷氨酸或聚天冬氨酸连接到化合物上以减少化合物的细胞摄取从而降低其细胞毒性，来改变抑制HGF / SF切割的苏氨酸和苏拉明相关多磺化化合物的方法。还提供含有至少一种除苏拉明以外的多磺化HGF / SF切割抑制化合物的药物组合物，以及含有至少一种HGF / SF切割抑制形式的苏拉明或苏拉明相关多磺化化合物的药物组合物，其被与化学部分结合，减少化合物进入细胞的摄取。本发明还包括其中这样的药物组合物被给予具有被HGF / SF刺激生长的肿瘤的哺乳动物，以抑制哺乳动物肿瘤生长或转移的方法。

9. 发明申请

WO1995001568A1 IMMUNOASSAY FOR SOLUBLE FIBRIN POLYMERS 审中-公开
标题翻译：可溶纤维素聚合物的免疫测定
公开(公告)号：WO1995001568A1
公开(公告)日：1995-01-12
申请号：PCT/US1994007087
申请日：1994-06-22
申请人： AMERICAN BIOGENETIC SCIENCES, INC.
发明人： AMERICAN BIOGENETIC SCIENCES, INC. , GARGAN, Paul, E. , PLOPLIS, Victoria, A. , PLEASANTS, Julian, R.
IPC分类号： G01N33/53
CPC分类号： G01N33/86 , A61K38/00 , A61K39/39533 , A61K47/6815 , A61K47/6843 , A61K47/6845 , C07K14/75 , C07K16/18 , C07K16/36 , G01N33/531 , G01N33/573 , G01N2333/745 , G01N2333/75 , G01N2333/972 , G01N2333/9723 , Y10S424/809 , Y10S435/962 , Y10S435/972 , Y10S435/975 , Y10S436/808 , A61K2300/00 , A61K38/49 , A61K38/164
摘要： The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized germfree animal. The invention also provides methods for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized germfree animal, for in vitro and in vivo clinical diagnostics and therapeutics. Also, the subject invention provides a fibrin-specific monoclonal antibody.
摘要翻译：本发明涉及生产单克隆抗体的方法。该方法利用免疫的无菌动物。本发明还提供了使用这种单克隆抗体的方法，以及衍生自免疫的无菌动物的多克隆抗体用于体外和体内临床诊断和治疗。而且，本发明提供了一种纤维蛋白特异性单克隆抗体。

10. 发明申请

WO1987005628A1 MINACTIVIN PRODUCED BY RECOMBINANT DNA TECHNOLOGY 审中-公开
标题翻译：由重组DNA技术生产的最小活性
公开(公告)号：WO1987005628A1
公开(公告)日：1987-09-24
申请号：PCT/AU1987000068
申请日：1987-03-13
申请人： BIOTECHNOLOGY AUSTRALIA PTY. LTD. , THE AUSTRALIAN NATIONAL UNIVERSITY
发明人： BIOTECHNOLOGY AUSTRALIA PTY. LTD. , THE AUSTRALIAN NATIONAL UNIVERSITY , ANTALIS, Toni, Marie , BARNES, Michael, Thomas , CLARKE, Michelle, Alison , DEVINE, Peter, Leonard , GOSS, Neil, Howard , LEHRBACH, Philip, Ralph
IPC分类号： C12N15/00
CPC分类号： G01N33/86 , A61K38/00 , C07K14/8132 , G01N2333/811 , G01N2333/9723
摘要： The present invention relates to the production of a novel human protein, minactivin, by recombinant DNA technology, the characterization of the gene sequence, and the expression and purification of large quantities of biologically active minactivin from a recombinant host. It also relates to the purification of biologically active native minactivin, as well as peptides derived from minactivin and their amino acid sequences.
摘要翻译：本发明涉及通过重组DNA技术生产新的人蛋白质灭活素，基因序列的表征，以及从重组宿主中大量生物活性灭活素的表达和纯化。它还涉及生物活性天然灭活素的纯化，以及衍生自灭活素及其氨基酸序列的肽。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式